Indinavir: A Rare Urinary Stone in HIV-1-Infected Patients – Occurrence and Crystal Properties

Abstract:

Article Preview

Info:

Periodical:

Materials Science Forum (Volumes 443-444)

Edited by:

Yvonne Andersson, Eric J. Mittemeijer and Udo Welzel

Pages:

407-410

Citation:

R. Tessadri et al., "Indinavir: A Rare Urinary Stone in HIV-1-Infected Patients – Occurrence and Crystal Properties", Materials Science Forum, Vols. 443-444, pp. 407-410, 2004

Online since:

January 2004

Export:

Price:

$38.00

[1] J.D. Rich, B. Ramratnam, M. Chinang, K.T. Tashima, J. Urol., 158 (1997), 2228.

[2] J.B. Kopp, K.D. Miller, J.A.M. Mican, I.M. Feuerstein, E. Vaughan, C. Baker, L.K. Pannell, J. Falloon, Am. Coll Phys., 127 (1997), 119-125.

[3] M. Daudon, L. Estépa, J.P. Viard, D. Joly, P., Lancet, 349 (1997), 1294-1295.

[4] Crixivan (Indinavir sulphate), prescribing information, Merck & Co., Inc., NJ, USA, September (2001).

[5] W.J. Reiter, H. Schön-Pernerstorfer, K. Dorfinger, J. Hofbauer, M. Marberger, J. Urol., 161 (1999), 1082-1084.

[6] E. Saltel, J.B. Angel, N.G. Futter, W.G. Walsh, K. Orourke, J.E. Mahoney, J. Urol, 164 (2000), 1895-1897.

[7] J.H. Lin, I.W. Chen, K.J. Vastag, D. Ostovic, Drug Metab. Dispos., 23 (1995), 730-735.

[8] J.P. Dieleman, S. Salahuddin, Y. S. Hsu, D.M. Burger, I.C. Gyssens, M.C.J.M. Sturkenboom, B.H. Ch. Stricker, D.J. Kok. J. Acquir. Immune Defic. Syndr., 28 (2001), 9-13.

DOI: https://doi.org/10.1097/00042560-200109010-00002

[9] J. Joost, R. Tessadri R, Urol. Res., Vol. 18/1 (1990), 73.

[10] J. Joost, R. Tessadri R, Eur. Urol., 9 (1983), 305-311.

[11] Otwinowski, Z.; Minor, W. Methods Enzymol. (1997), 276, 307.

Fetching data from Crossref.
This may take some time to load.